Your browser doesn't support javascript.
loading
A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.
Smith, Patrick F; Krishnarajah, Janakan; Nunn, Philip A; Hill, Ron J; Karr, Dane; Tam, D; Masjedizadeh, Mohammad; Funk, Jens O; Gourlay, Steve G.
Affiliation
  • Smith PF; d3 Medicine, A Certara Company, Parsippany, New Jersey, USA.
  • Krishnarajah J; Linear Clinical Research, Perth, Australia.
  • Nunn PA; Principia Biopharma, Melbourne, Australia.
  • Hill RJ; Principia Biopharma, Melbourne, Australia.
  • Karr D; Principia Biopharma, Melbourne, Australia.
  • Tam D; Principia Biopharma, Melbourne, Australia.
  • Masjedizadeh M; Principia Biopharma, Melbourne, Australia.
  • Funk JO; Principia Biopharma, Melbourne, Australia.
  • Gourlay SG; Principia Biopharma, Melbourne, Australia.
Br J Clin Pharmacol ; 83(11): 2367-2376, 2017 Nov.
Article in En | MEDLINE | ID: mdl-28636208
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein-Tyrosine Kinases / Leukocytes, Mononuclear / Protein Kinase Inhibitors Type of study: Clinical_trials Limits: Adult / Humans / Male Language: En Journal: Br J Clin Pharmacol Year: 2017 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein-Tyrosine Kinases / Leukocytes, Mononuclear / Protein Kinase Inhibitors Type of study: Clinical_trials Limits: Adult / Humans / Male Language: En Journal: Br J Clin Pharmacol Year: 2017 Document type: Article Affiliation country: Country of publication: